Epstein-Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA

Immunology

Volumn 141, Issue 2, 2014, Pages 276-285

  Fattal, Ittai ^a,b   Shental, Noam ^c   Molad, Yair ^d   Gabrielli, Armando ^e   Pokroy Shapira, Elisheva ^d   Oren, Shirly ^d   Livneh, Avi ^f   Langevitz, Pnina ^f   Pauzner, Rachel ^f   Sarig, Ofer ^g   Gafter, Uzi ^b   Domany, Eytan ^a   Cohen, Irun R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c OPEN UNIVERSITY OF ISRAEL   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SHEBA MEDICAL CENTER   (Israel)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anti dsDNA; Autoantibodies; Epstein Barr virus; Scleroderma; Systemic lupus erythematosus

Indexed keywords

CARDIOLIPIN; COLLAGEN TYPE 3; DNA ANTIBODY; DNA TOPOISOMERASE; EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; MYELOPEROXIDASE; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CENTROMERE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; NONHUMAN; PEMPHIGUS; PREDICTIVE VALUE; PRIORITY JOURNAL; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-DSDNA; AUTOANTIBODIES; EPSTEIN-BARR VIRUS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, SYSTEMIC;

EID: 84891898633     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12200     Document Type: Article

References (30)

1. Sherer Y, Gorstein A, Fritzler MJ et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34:501-37.
2. Criteria published by EM Tan et al. Arthritis Rheum 1982; 25:1271, updated by MC Hochberg, Arthritis Rheum 1997; 40:1725.
3. James JA, Kaufman KM, Farris AD et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019-26.
4. James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:462-7.
5. Carapetis JR, Steer AC, Mulholland EK et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685-94.
6. Fattal I, Shental N, Mevorach D et al. An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunology 2010; 130:337-43.
7. Stollerman GH, Dale JB. The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin Infect Dis 2008; 46:1038-45.
8. Quintana FJ, Merbl Y, Sahar E et al. Antigen-chip technology for accessing global information about the state of the body. Lupus 2006; 15:428-30.
9. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc B 1995; 57:289-300.
10. Quan LZ, Chun X, Tianfu W et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115:3428-39.
11. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969-76.
12. Howie JB, Helyer BJ. The immunology and pathology of NZB mice. Adv Immunol 1968; 9:215-66.
13. Kyttaris VC, Juang Y, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2005; 17:518-22.
14. + cells to support autoantibody synthesis. Arthritis Rheum 1990; 33:1216-25.
15. Suzuki N, Ichino M, Mihara S et al. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41:344-53.
16. + regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10:849-59.
17. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol 2000; 71:108-17.
18. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008; 41:298-328.
19. Gauld SB, De Santis JL, Kulinski JM, McGraw JA, Leonardo SM, Ruder EA, Maier W, Tarakanova VL. Modulation of B-cell tolerance by murine gammaherpesvirus 68 infection: requirement for Orf73 viral gene expression and follicular helper T cells. Immunology 2013; 139:197-204.
20. Kang I, Quan T, Nolasco H et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004; 172:1287-94.
21. Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007; 117:712-8.
22. Cohen IR, Cooke A. Natural autoantibodies might prevent autoimmune disease. Immunol Today 1986; 7:363-4.
23. Madi A, Bransburg-Zabary S, Kenett DY et al. The natural autoantibody repertoire in newborns and adults: a current overview. Adv Exp Med Biol 2012; 750:198-212.
24. Herkel J, Mimran A, Erez N et al. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J Autoimmun 2001; 17:63-9.
25. Herkel J, Kam N, Erez N et al. Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA. Eur J Immunol 2004; 34:3623-32.
26. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012; 28:128-36.
27. Miret C, Molina R, Filella X et al. Font J. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Tumour Biol 2003; 24:185-8.
28. de Rosbo NK, Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. Autoimmun 1998; 11:287-99.
29. Quintana FJ, Farez MF, Viglietta V et al. Antigen microarray identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008; 105:18889-94.
30. Hueber W, Kidd BA, Tomooka BH et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005; 52:2645-55.